JP2025508374A5 - - Google Patents

Info

Publication number
JP2025508374A5
JP2025508374A5 JP2024547535A JP2024547535A JP2025508374A5 JP 2025508374 A5 JP2025508374 A5 JP 2025508374A5 JP 2024547535 A JP2024547535 A JP 2024547535A JP 2024547535 A JP2024547535 A JP 2024547535A JP 2025508374 A5 JP2025508374 A5 JP 2025508374A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547535A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508374A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/012836 external-priority patent/WO2023154482A1/en
Publication of JP2025508374A publication Critical patent/JP2025508374A/ja
Publication of JP2025508374A5 publication Critical patent/JP2025508374A5/ja
Pending legal-status Critical Current

Links

JP2024547535A 2022-02-10 2023-02-10 Ｔ細胞及びｎｋ細胞エンゲージャー Pending JP2025508374A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263308800P 2022-02-10 2022-02-10
US63/308,800 2022-02-10
PCT/US2023/012836 WO2023154482A1 (en) 2022-02-10 2023-02-10 T cell and nk cell engagers

Publications (2)

Publication Number Publication Date
JP2025508374A JP2025508374A (ja) 2025-03-26
JP2025508374A5 true JP2025508374A5 (enExample) 2026-02-18

Family

ID=87564955

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547535A Pending JP2025508374A (ja) 2022-02-10 2023-02-10 Ｔ細胞及びｎｋ細胞エンゲージャー

Country Status (10)

Country Link
US (1) US20250138018A1 (enExample)
EP (1) EP4476261A4 (enExample)
JP (1) JP2025508374A (enExample)
KR (1) KR20250004624A (enExample)
CN (1) CN118871470A (enExample)
AU (1) AU2023217006A1 (enExample)
CA (1) CA3243109A1 (enExample)
IL (1) IL314641A (enExample)
MX (1) MX2024009712A (enExample)
WO (1) WO2023154482A1 (enExample)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140227293A1 (en) * 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
PE20181326A1 (es) * 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
AU2018296067B2 (en) * 2017-07-06 2021-06-10 Merus B.V. Binding molecules that modulate a biological activity expressed by a cell
EP3800201A1 (en) * 2019-10-01 2021-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd28h stimulation enhances nk cell killing activities

Similar Documents

Publication Publication Date Title
JP7611931B2 (ja) ガイダンス及びナビゲーションコントロール（ｇｎｃ）抗体様タンパク質、その製造方法及び使用方法
JP2022541435A5 (enExample)
JP7592712B2 (ja) ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法
JP2024001073A5 (enExample)
JP2021512604A5 (enExample)
US20230374157A1 (en) Specificy-enhanced bispecific antibody (seba)
US20240309099A1 (en) Bispecific tetravalent antibody targeting egfr and her3
CN119173540A (zh) 多特异性抗体及其用途
JP7812988B2 (ja) Ｌｅｗｉｓ Ｙに対するヒト化抗体
Lee et al. Effective clearance of rituximab-resistant tumor cells by breaking the mirror-symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20
JP2025508374A5 (enExample)
JP7641292B2 (ja) 抗ｃｄ１９抗体、その使用方法及び製造方法
CN120035449A (zh) 一种结合baffr和cd3的双特异性抗体及其应用
JP2024508597A5 (enExample)
AU2024237201A1 (en) Isolated bispecific antibody that specifically binds to cd3 and tumor antigen, and use thereof
WO2025117872A1 (en) Bispecific antibody-like protein and methods of making and using thereof
WO2025117871A1 (en) Bispecific tetravalent antibody targeting her2 and her3
JP2023539883A5 (enExample)